Lanoxin (Digoxin)

Digoxin inhibits the Na⁺/K⁺‑ATPase pump on heart muscle cells, leading to higher intracellular sodium. This reduces the activity of the sodium‑calcium exchanger, causing calcium to accumulate inside the cells. The increased calcium enhances the strength of each heartbeat (positive inotropy) and also slows conduction through the atrioventricular node, helping control heart rate.

The appropriate dose of Lanoxin is individualized based on the patient’s age, kidney function, body weight, and clinical response. A qualified prescriber determines the starting dose and any adjustments, often guided by serum digoxin concentration and clinical monitoring.

Lanoxin is classified as Pregnancy Category C, meaning risk cannot be ruled out. It should be used only when the potential benefit justifies the potential fetal risk. Limited data are available for breastfeeding, so clinicians should weigh the advantages against possible exposure to the infant.

To request Lanoxin, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

The primary alternative to digoxin in heart failure and atrial arrhythmias includes beta‑blockers, ACE inhibitors, ARBs, and newer agents such as sacubitril/valsartan. Unlike those classes, digoxin provides a direct positive inotropic effect and specific AV‑node slowing, but it requires careful monitoring for toxicity, whereas many alternatives have broader safety margins.

Lanoxin tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original packaging to protect from moisture and light. Do not store in a refrigerator or freezer, and keep out of reach of children.

Lanoxin is supplied as oral tablets. The tablet is swallowed whole with a glass of water and may be taken with or without food. Patients should follow the prescriber’s instructions regarding timing and any dietary considerations, such as avoiding large amounts of high‑fiber meals that could affect absorption.

The most serious risks include cardiac arrhythmias such as ventricular tachycardia or fibrillation, severe bradycardia, and digoxin toxicity manifested by nausea, visual changes, and electrolyte disturbances like hyperkalemia. Prompt medical evaluation is essential if any of these symptoms arise.

Lanoxin is contraindicated in patients with ventricular fibrillation, certain high‑grade AV blocks without a pacemaker, known hypersensitivity to digoxin or other cardiac glycosides, and in those with uncontrolled electrolyte imbalances that could predispose to toxicity. Clinicians must assess each patient’s medical history before initiating therapy.